

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

Assignment ID: PATI707986

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	RELEASE OF SECURITY INTEREST IN PATENT COLLATERAL (063543/0374)
CONVEYING PARTY DATA	
Name	Execution Date
JPMORGAN CHASE BANK, N.A.	12/18/2024
RECEIVING PARTY DATA	
Company Name:	Catalent Greenville, Inc.
Street Address:	1240 SUGG PARKWAY
City:	GREENVILLE
State/Country:	NORTH CAROLINA
Postal Code:	27834
PROPERTY NUMBERS Total: 1	
Property Type	Number
Patent Number:	8858993
CORRESPONDENCE DATA	
Fax Number:	
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
Phone:	2023704750
Email:	ipteam@cogencyglobal.com
Correspondent Name:	Joanna McCall
Address Line 1:	1025 Connecticut Ave NW, Suite 712
Address Line 2:	Cogency Global Inc.
Address Line 4:	Washington, DISTRICT OF COLUMBIA 20036
ATTORNEY DOCKET NUMBER:	2599982 JME
NAME OF SUBMITTER:	Andrew Hackett
SIGNATURE:	Andrew Hackett
DATE SIGNED:	12/19/2024
Total Attachments: 9	
source=E Catalent - Patent Release [Executed] (063543-0374 with cover page)#page1.tiff	
source=E Catalent - Patent Release [Executed] (063543-0374 with cover page)#page2.tiff	
source=E Catalent - Patent Release [Executed] (063543-0374 with cover page)#page3.tiff	
source=E Catalent - Patent Release [Executed] (063543-0374 with cover page)#page4.tiff	

source=E Catalent - Patent Release [Executed] (063543-0374 with cover page)#page5.tiff
source=E Catalent - Patent Release [Executed] (063543-0374 with cover page)#page6.tiff
source=E Catalent - Patent Release [Executed] (063543-0374 with cover page)#page7.tiff
source=E Catalent - Patent Release [Executed] (063543-0374 with cover page)#page8.tiff
source=E Catalent - Patent Release [Executed] (063543-0374 with cover page)#page9.tiff

**RELEASE OF
SECURITY INTEREST IN PATENT COLLATERAL**

THIS RELEASE OF SECURITY INTEREST IN PATENT COLLATERAL (this “Release”), is entered into as of December 18, 2024 by **JPMORGAN CHASE BANK, N.A.**, as collateral agent for the Secured Parties (in such capacity, the “Collateral Agent”) in connection with the grant of security interests in certain patents by (i) Catalent Pharma Solutions, LLC, (ii) R.P. Scherer Technologies, Inc., (iii) R.P. Scherer Technologies, LLC, (iv) R.P. Scherer Corporation, (v) Catalent CTS (Kansas City), LLC, (vi) Redwood Bioscience, Inc. and (vii) Catalent Greenville, Inc. (each a “Grantor” and, collectively, the “Grantors”), in favor of the Predecessor Collateral Agent and Collateral Agent, as applicable. Capitalized terms used and not otherwise defined herein have the meanings assigned to them in the Security Agreement, dated as of April 10, 2007 (as amended, restated, amended and restated, supplemented or otherwise modified from time to time prior to the date hereof), among PTS ACQUISITION CORP., as borrower prior to the Acquisition, CARDINAL HEALTH 409, INC., as borrower after the Acquisition, PTS INTERMEDIATE HOLDINGS LLC, as Holdings, certain other subsidiaries of Holdings as identified therein and Morgan Stanley Senior Funding, Inc., as collateral agent (in such capacity, the “Predecessor Collateral Agent”) and the Collateral Agent.

WITNESSETH:

WHEREAS, the applicable Grantors listed therein and the Collateral Agent and Predecessor Collateral Agent, as applicable, entered into (i) that certain Intellectual Property Security Agreement, dated as of April 10, 2007 (the “2007 IP Security Agreement”), (ii) that certain Intellectual Property Security Agreement Supplement, dated as of April 2, 2012 (the “2012 IP Security Agreement”), (iii) that certain Intellectual Property Security Agreement Supplement, dated as of November 14, 2014 (the “2014 IP Security Agreement”), (iv) that certain Additional Collateral Intellectual Property Security Agreement Supplement, dated as of May 17, 2019 (the “2019 IP Security Agreement”) and (v) that certain Additional Restricted Subsidiary Intellectual Property Security Agreement Supplement, dated as of December 2, 2022 (the “2022 IP Security Agreement” and, collectively with the 2007 IP Security Agreement, 2012 IP Security Agreement, 2014 IP Security Agreement, and 2019 IP Security Agreement, the “Patent Security Agreements”), pursuant to which the Grantors granted to the Collateral Agent, for the benefit of the Secured Parties, a continuing security interest in the Patent Collateral (as defined below);

WHEREAS, (i) the 2007 IP Security Agreement was recorded with the United States Patent and Trademark Office on May 22, 2007 at Reel 019323, Frame 0302 and assigned to the Collateral Agent pursuant to that certain Notice of Succession of Agency and Assignment of Security Interest in Intellectual Property, dated as of May 17, 2019 (the “Assignment of Security Interest”), recorded with the United States Patent and Trademark Office on May 17, 2019 at Reel 049217, Frame 0981, (ii) the 2012 IP Security Agreement was recorded with the United States Patent and Trademark Office on September 19, 2012 at Reel 029007, Frame 0559 and assigned to the Collateral Agent pursuant to the Assignment of Security Interest, recorded with the United States Patent and Trademark Office on May 17, 2019 at Reel 049217, Frame 0981, (iii) the 2014 IP Security Agreement was recorded with the United States Patent and Trademark Office on November 21, 2014 at Reel 034414, Frame 0616 and assigned to the Collateral Agent pursuant to the Assignment of Security Interest, recorded with the United States Patent and Trademark Office on May 17, 2019 at Reel 049217, Frame 0981, (iv) the 2019 IP Security Agreement was recorded with the United States Patent and Trademark Office on May 20, 2019 at Reel 049221, Frame 0673 and (v) the 2022 IP Security Agreement was recorded with the United States Patent and Trademark Office on May 4, 2023 at Reel 063543, Frame 0374;

WHEREAS, the Collateral Agent now desires to terminate and release the entirety of its Liens on and security interests in the Patents set forth on Schedule I hereto (the "Patents") and in the Patent Collateral.

NOW, THEREFORE, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Agent hereby agrees as follows:

1. Definitions. The term "Patent Collateral", as used herein, means (a) each Patent and (b) all proceeds of and revenues from the foregoing, including, without limitation, all proceeds of and revenues from any claim by each respective Grantor against third parties for past, present or future infringement of any Patent owned by any Grantor.

2. Release of Security Interest. The Collateral Agent hereby (i) terminates, cancels, releases and discharges all of its Liens on and security interests in the Patent Collateral without representation, warranty or recourse of any kind or nature, and (ii) reassigns any right, title and interest it may have in, to and under the Patent Collateral to each respective Grantor.

3. Further Assurances. The Collateral Agent hereby authorizes the Borrower or any of its designees to record this Release with the United States Patent and Trademark Office and any other offices as may be necessary to carry out the intention of this Release, and to the extent applicable, the Collateral Agent authorizes and requests that the United States Patent and Trademark Office record this Release.

The Collateral Agent shall, at any Grantor's sole cost and expense, and without representation, warranty or recourse, take all further actions, and provide to such Grantor, its successors, assigns or other legal representatives, all such cooperation and assistance (including, without limitation, the execution and delivery of any and all documents or other instruments) reasonably requested by such Grantor to more fully and effectively effectuate the purposes of this Release.

4. Governing Law. THIS RELEASE, AND THE RIGHTS AND OBLIGATIONS OF THE PARTIES HEREUNDER SHALL BE GOVERNED BY, AND CONSTRUED AND INTERPRETED IN ACCORDANCE WITH, THE LAW OF THE STATE OF NEW YORK, WITHOUT REFERENCE TO CONFLICTS OF LAW PROVISIONS.

5. Miscellaneous. Delivery of an executed signature page to this Release by facsimile or electronic transmission (including .pdf file) shall be effective as delivery of an original signature.

[Remainder of page intentionally left blank.]

IN WITNESS WHEREOF, the undersigned has caused this Release to be duly executed and delivered by its respective officers thereunto duly authorized as of the day and year first above written.

JPMORGAN CHASE BANK, N.A.,
as Collateral Agent

By: 
Name: Maurice Dattas
Title: Vice President

[SIGNATURE PAGE TO PATENT RELEASE]

PATENT
REEL: 069751 FRAME: 0245

SCHEDULE I

2007 IP Security Agreement, Patents
Recorded at Reel/Frame 019323/0302

	Owner	Patent Title	Appl. No. Filing Date	Patent No. Issue Date
1.	Catalent Pharma Solutions, LLC	Host Cells Containing Multiple Integrating Vectors	09897511 06/29/2001	6852510 02/08/2005
2.	Catalent Pharma Solutions, LLC	Host Cells Containing Multiple Integrating Vectors	11018895 12/21/2004	7332333 02/19/2008
3.	Catalent Pharma Solutions, LLC	Expression Vectors	10947881 09/23/2004	7378273 05/27/2008
4.	Catalent Pharma Solutions, LLC	Fusion Antibodies	10900928 07/28/2004	7696322 04/13/2010
5.	Catalent Pharma Solutions, LLC	Retrovirus-based genomic screening	10397569 03/26/2003	7384738 06/10/2008
7.	R.P. Scherer Technologies, Inc.	Constricted Neck Blister Pack And Apparatus And Method For Making The Same	09775952 02/02/2001	6588180 07/08/2003
8.	R.P. Scherer Technologies, Inc. and Cana Lab Corporation	Oral Pharmaceutical Compositions Containing Long-Chain Triglycerides And Liphophilic Surfactants	09914576 12/21/2001	6652880 11/25/2003
9.	R.P. Scherer Technologies, Inc.	Opioid Agonist In A Fast Dispersing Dosage Form	09936060 01/14/2002	6680071 01/20/2004
10.	R.P. Scherer Technologies, Inc.	Fast-Dispersing Dosage Forms Containing Fish Gelatin	09959018 10/16/2001	6709669 03/23/2004
11.	R.P. Scherer Technologies, Inc.	Antihistamine Formulations For Soft Gelatin Dosage Forms	09909313 07/20/2001	6720002 04/13/2004
12.	R.P. Scherer Technologies, Inc.	Process For Preparing Pharmaceutical Compositions For Use With Soft Gelatin Formulations	09649947 08/29/2000	6387400 05/14/2002
13.	R.P. Scherer Technologies, Inc.	Opioid Agonist In A Fast Dispersing Dosage Form	10647761 08/25/2003	7090866 08/15/2006
14.	R.P. Scherer Technologies, Inc.	Fast-dispersing dosage forms containing fish gelatin	10685728 10/14/2003	9192580 11/24/2015
15.	R.P. Scherer Technologies, Inc.	Antihistamine Formulations For Soft Capsule Dosage Forms	10384868 03/10/2003	7201921 04/10/2007
16.	R.P. Scherer Technologies, Inc.	Child-resistant blister pack	10141288 05/08/2002	6830153 12/14/2004
19.	R.P. Scherer Technologies, Inc.	Apparatus and method for manufacturing encapsulated products	10016352 11/02/2001	6884060 04/26/2005
20.	R.P. Scherer Technologies, Inc.	Oral pharmaceutical composition for soft capsules containing	10161454 05/31/2002	6890558 05/10/2005

		vinorelbine and method of treatment		
21.	R.P. Scherer Technologies, LLC	Oral pharmaceutical composition for soft capsules containing vinorelbine and method of treatment	11082720 03/18/2005	7658943 02/09/2010
22.	R.P. Scherer Technologies, Inc.	Acetaminophen compositions	09990497 11/21/2001	7029698 04/18/2006
23.	R.P. Scherer Technologies, Inc.	Nozzle structure	11437012 05/18/2006	7575182 08/18/2009
25.	R.P. Scherer Technologies, Inc.	Chewable soft capsules containing ungelatinized starch	10739451 12/17/2003	9241902 01/26/2016
26.	R.P. Scherer Technologies, LLC	Ingestible compositions containing an odoriferous oil	10466896 01/12/2004	9532585 01/03/2017
27.	R.P. Scherer Technologies, Inc.	Vial	29189356 09/03/2003	D517207 03/14/2006
28.	R.P. Scherer Technologies, Inc.	Vial	29259816 05/16/2006	D596740 07/21/2009
29.	R.P. Scherer Technologies, Inc.	Dispersion of taste masked crystals or granules of active substances, chewable soft capsules filled with said dispersion, and process for preparing same	10543084 01/26/2006	
30.	R.P. Scherer Technologies, Inc.	Method and apparatus for making a blister pack with indicia	10298893 11/18/2002	6890472 05/10/2005
31.	R.P. Scherer Technologies, Inc.	Apparatus for making embossed blister pack	10075824 02/13/2002	7121822 10/17/2006
32.	R.P. Scherer Technologies, Inc.	Embossed blister pack	10973739 04/25/2005	7704583 04/27/2010
33.	R.P. Scherer Technologies, Inc.	Method and apparatus for printing a ribbon for packaging gelatin capsules	10236669 09/06/2002	7213511 05/08/2007
34.	R.P. Scherer Technologies, Inc.	Process to minimize polymorphism	11650672 01/08/2007	
35.	R.P. Scherer Technologies, LLC	System and method for dusting soft capsules	11651370 01/09/2007	7908992 03/22/2011
36.	R.P. Scherer Technologies, LLC	Process for formulating fast dispersing dosage forms comprising at least one fish gelatin selected on the basis of molecular weight	10860106 06/03/2004	7972621 07/05/2011
37.	R.P. Scherer Technologies, LLC	Non-gelatin soft capsule system	10984205 11/08/2004	8231896 07/31/2012
38.	R.P. Scherer Technologies, LLC	Formulations containing substituted imidazole derivatives	10534117 10/06/2005	9717681 08/01/2017

39.	R.P. Scherer Corporation	Fast dispersing dosage forms essentially free of mammalian gelatin	09887604 06/22/2001	6509040 01/21/2003
-----	--------------------------	--	------------------------	-----------------------

2012 IP Security Agreement, Patents
Recorded at Reel/Frame 029007/0559

	Owner	Patent Title	Appl. No. Filing Date	Patent No. Issue Date
1.	Catalent CTS (Kansas City), LLC	Apparatus and method for filling containers	12233920 09/19/2008	8607828 12/17/2013

2014 IP Security Agreement, Patents
Recorded at Reel/Frame 034414/0616

	Owner	Patent Title	Appl. No. Filing Date	Patent No. Issue Date
1.	Redwood Bioscience, Inc.	Aldehyde-tagged protein-based drug carriers and methods of use	12706679 02/16/2010	9238878 01/19/2016
2.	Redwood Bioscience, Inc.	Hydrazinyl-indole compounds and methods for producing a conjugate	13794159 03/11/2013	9310374 04/12/2016
3.	Redwood Bioscience, Inc.	Aldehyde-Tagged Immunoglobulin Polypeptides and Methods of Use Thereof	13350676 01/13/2012	9540438 01/10/2017

2019 IP Security Agreement, Patents
Recorded at Reel/Frame 049221/0673

	Owner	Patent Title	Appl. No. Filing Date	Patent No. Issue Date
1.	R.P. Scherer Technologies, LLC	Automated Sterilization Process Integrated with a Blow Fill Seal Machine	13902385 05/24/2013	9034249 05/19/2015
2.	R.P. Scherer Technologies, LLC	Automated Sterilization Process Integrated with a Blow Fill Seal Machine	14656858 03/13/2015	9533065 01/03/2017
3.	R.P. Scherer Technologies, LLC	Molded Container With Opener And Method For Use	12494873 06/30/2009	10086984 10/02/2018
4.	R.P. Scherer Technologies, LLC	Molded Container With Opener And Method For Use	16108394 08/22/2018	
5.	Catalent Pharma Solutions, LLC	Veterinary Decorin Compositions And Use Thereof	14258197 04/22/2014	10137168 11/27/2018

6.	Catalent Pharma Solutions, LLC	Antibody Libraries	12493851 06/29/2009	8222188 07/17/2012
7.	Catalent Pharma Solutions, LLC	Fusion Antibodies	12720108 03/09/2010	9541547 01/10/2017
8.	R.P. Scherer Technologies, LLC	Process Of Manufacturing A Lyophilized Fast Dissolving, Multi-Phasic Dosage Form	12724601 03/16/2010	
9.	Catalent Pharma Solutions, LLC	Decorin Compositions And Use Thereof	13419045 03/13/2012	
11.	R.P. Scherer Technologies, Inc.	Process to minimize polymorphism	12393584 02/26/2009	
12.	R.P. Scherer Technologies, Inc.	Cap	29257375 04/03/2006	
13.	R.P. Scherer Technologies, LLC	Hydrazinyl-Substituted Heteroaryl Compounds and Methods for Producing a Conjugate	15459887 03/15/2017	10195283 02/05/2019
14.	R.P. Scherer Technologies, LLC	Hydrazinyl-Substituted Heteroaryl Compounds and Methods for Producing a Conjugate	16219398 12/13/2018	
15.	R.P. Scherer Technologies, LLC	Non-gelatin soft capsule system	13543244 07/06/2012	8377470 02/19/2013
16.	R.P. Scherer Technologies, LLC	Chemical modification of proteins	12918678 02/15/2011	9346851 05/24/2016
17.	R.P. Scherer Technologies, LLC and Alk-Abello A/S	Allergen dosage form	14287920 05/27/2014	9408805 08/09/2016
18.	R.P. Scherer Technologies, LLC and Alk-Abello A/S	Allergen dosage form	12098150 04/04/2008	9415015 08/16/2016
19.	R.P. Scherer Technologies, LLC	Process of manufacturing a stable softgel capsule containing microencapsulated probiotic bacteria	13204979 08/08/2011	9427012 08/30/2016
20.	R.P. Scherer Technologies, LLC	Encased-pellet tablets	14484754 09/12/2014	9566248 02/14/2017
22.	R.P. Scherer Technologies, LLC	Stable montelukast solution	14633585 02/27/2015	9717684 08/01/2017
23.	R.P. Scherer Technologies, LLC	Oral Solid Dosage Form Containing Nanoparticles and Process of Formulating the Same Using Fish Gelatin	12560813 09/16/2009	9775819 10/03/2017

26.	R.P. Scherer Technologies, LLC	Activated Formylglycine-Generating Enzymes and Methods of Producing and Using the Same	14975403 12/18/2015	9951367 04/24/2018
27.	R.P. Scherer Technologies, LLC	Activated Formylglycine-Generating Enzymes and Methods of Producing and Using the Same	15862312 01/04/2018	
28.	R.P. Scherer Technologies, LLC	Oral vaccine fast-dissolving dosage form using starch	13270411 10/11/2011	9956169 05/01/2018
29.	Redwood Bioscience, Inc.	Anti-Her2 Antibody-Maytansine Conjugates and Methods of Use Thereof	14723393 05/27/2015	10124070 11/13/2018
30.	Redwood Bioscience, Inc.	Aldehyde-Tagged Immunoglobulin Polypeptides and Methods of Use Thereof	15362396 11/28/2016	10183998 01/22/2019
31.	Redwood Bioscience, Inc.	Antibody Specific for CD22 and Methods of Use Thereof	13942140 07/15/2013	9181343 11/10/2015
32.	Redwood Bioscience, Inc.	Hydrazinyl-pyrrolo compounds and methods for producing a conjugate	14555283 11/26/2014	9493413 11/15/2016
33.	Redwood Bioscience, Inc.	Compounds and methods for producing a conjugate	14704802 05/05/2015	9579390 02/28/2017
34.	Redwood Bioscience, Inc.	Aldehyde-Tagged Protein-Based Drug Carriers and Methods of Use	14959360 12/04/2015	9879249 01/30/2018
35.	Redwood Bioscience, Inc.	Antibody Specific for CD22 and Methods of Use Thereof	14878871 10/08/2015	
36.	Redwood Bioscience, Inc.	Antibody Specific for CD22 and Methods of Use Thereof	16289177 02/28/2019	
37.	Redwood Bioscience, Inc.	Hydrazinyl-indole compounds and methods for producing a conjugate	15057847 03/01/2016	
38.	Redwood Bioscience, Inc.	Hydrazinyl-pyrrolo compounds and methods for producing a conjugate	15276479 09/26/2016	
39.	Redwood Bioscience, Inc.	Hydrazinyl-Indole Compounds and Methods for Producing a Conjugate	15799846 10/31/2017	
40.	Redwood Bioscience, Inc.	Hydrazinyl-Indole Compounds and Methods for Producing a Conjugate	15057847 03/01/2016	9833515 12/05/2017
41.	Redwood Bioscience, Inc.	Anti-her2 antibody-maytansine conjugates and methods of use thereof	16143141 09/26/2018	

2022 IP Security Agreement, Patents
Recorded at Reel/Frame 063543/0374

	Owner	Patent Title	Appl. No. Filing Date	Patent No. Issue Date
--	-------	--------------	--------------------------	--------------------------

1.	Catalent Greenville, Inc.	COATED TABLET WITH ZERO-ORDER OF NEAR ZERO-ORDER RELEASE KINESTICS	11488547 July 18, 2006	8858993 October 14, 2014
----	---------------------------	--	---------------------------	--------------------------------